Experimental study on the protective effect of puerarin to Parkinson disease

Abstract

The protective effect of puerarin on the Parkinson disease (PD) mice with decreased estrogen level was investigated in order to develop a new potential medicine as a substitute for estrogen for preventing and treating PD. By using immunohistochemical method of avidinbiotin peroxidase complex (ABC), the distribution of the cells positive for tyrosine hydroxylase (TH) and fibres in the substantia nigra of the mouse were observed. These mice were divided into three groups randomly: group A, normal-female-mouse models; group B containing three subgroups, B1 (normal saline), B2 (estrogen), B3 (puerarin); group C containing three sub groups, C1 (normal saline), C2 (estrogen), C3 (puerarin). By using TUNEL the numbers of apoptosis cells in every visual field was counted and the difference between the experimental group and control group was compared. The results showed the numbers of the cells positive for TH were more and the numbers of apoptosis cells were less in the normal-female-mouse models group than in the group of model made, after ovariosteresis and the group of model made before ovariosteresis (P<0.05), respectively. However, there was no significant difference, between the group given estrogen/puerarin and the controls, and between the group given estrogen and given puerarin. (P>0.05). It was suggested that puerarin may have protective effect on the nigral neurons to PD. Moreover, the protective effect might serve as a surrogate of estrogen and be associated with the apoptosis.

Keywords

Parkinson disease / puerarin / protection / apoptosis

References

[1] RichardE, HeikkilaR E, HessandR C, et al. . Dopaminergic neurotoxicity of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in mice. Science, 1984, 2241451-1451

[2] AraiN, MisugiK, GoshimaY, et al. . Evaluation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-treated C57 black mouse model for Parkinsonism. Brain Res, 1990, 515(1–2): 57-57

[3] ShepherdJ E. Effects of estrogen on cognition, mood, and degenerative brain diseases. J Am Pharm Assoc (Wash), 2001, 41(2): 221-221

[4] PatisaulH B, DindoM, WhittenP L, et al. . Soy isoflavone supplements antagonize reproductive behavior and estrogen receptor alpha- and beta-dependent gene expression in the brain. Endocrinology, 2001, 142(7): 2946-2946

[5] CyrM, CalonF, MorissetteM, et al. . Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des, 2000, 6(12): 1287-1287

[6] KnightD C, EdenA. A review of the clinical effects of phyto-estrogens. Obstetrics Gynecology, 1996, 87(5): 897-897

[7] SawadaH, ShimobamaS. Neuroprotective effects of estradiol in mesencephalic dopaminergic neuron. Neurosci Biobehav Rev, 2000, 24(1): 143-143

[8] SawadaH, IbiM, KiharaT, et al. . Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res, 1998, 54(5): 707-707

[9] SawadaH, IbiM, KiharaT, et al. . Mechanisms of antiapoptotic effects of estrogens in dopaminergic neurons. FASEB J, 2000, 14(9): 1202-1202